Sökning: "IDH1"
Visar resultat 1 - 5 av 8 avhandlingar innehållade ordet IDH1.
1. Genotype-phenotype studies in brain tumors
Sammanfattning : Meningioma and glioma are the most common primary brain tumors, but their etiologies are largely unknown. Although meningioma is usually benign, their intracranial location can lead to lethal consequences, and despite progress in surgery, radiotherapy, and chemotherapy the prognosis for patients with glioma remains poor. LÄS MER
2. Prognostic markers in acute myeloid leukemia : A candidate gene approach
Sammanfattning : The standard treatment of acute myeloid leukemia (AML) consists of induction chemotherapy, most commonly daunorubicin together with the nucleoside analogue cytarabine (Ara-C), followed by consolidation chemotherapy and in selected cases allogenic stem cell transplantation (allo-SCT). Despite a high initial response rate, a considerable proportion of all AML cases eventually suffer from relapse and the five-year overall survival rate in patients >60 years is only around 15%. LÄS MER
3. Modeling and investigations of high-grade glioma to understand tumorigenesis and heterogeneity
Sammanfattning : Glioblastoma (GBM) is the most common primary malignant brain tumor. As per 2021 WHO classification, the corresponding diagnosis in children is called diffuse pediatric-type high-grade glioma (pHGG). In both cases tumors are histone 3 (H3) and isocitrate dehydrogenase 1/2 (IDH1/2) wildtype (wt). LÄS MER
4. Molecular genetic studies on Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia - with focus on prognostic markers
Sammanfattning : The present thesis is focused on the prognostic value of genetic variations and alterations in the initiation and development of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) patients. Several prognostic markers based on genetic or chromosomal aberrations are today used in clinic in these heterogeneous diseases. LÄS MER
5. Prognostic and biological implications of epigenetic changes in leukemia
Sammanfattning : The field of epigenetic research in hematology and oncology is rapidly expanding. Even so, reliable data linking epigenetic changes to clinical outcomes are scarce. We conducted two retrospective studies in AML. LÄS MER